About Us
What We Do
Helping Patients in Need of New Treatment Options
Salarius Pharmaceuticals is a cancer-focused biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop new therapies to address gene dysregulation, with potential to work in both liquid and solid tumors. Our lead protein inhibitor, seclidemstat (SP-2577), represents a potential paradigm shift in the treatment of cancer. We are targeting Ewing sarcoma, a devastating bone cancer affecting pediatric, adolescent, and young adult patients, for which no targeted therapies are currently available. We are collaborating with the MD Anderson Cancer Center to target hematologic or blood cancers.
SP-3164 is our lead targeted protein degrader. It is a differentiated molecular glue that promotes selective degradation of the transcription factors Ikaros and Aiolos and has the potential to treat hematological cancers and solid tumors. SP-3164 is expected to enter the clinic in the second half of 2023.
Leadership Team
-
Bio
David J. Arthur
Chief Executive Officer
David J. Arthur
Chief Executive OfficerMr. Arthur is a senior life sciences executive with more than 35 years of US and global pharmaceutical experience. During his career, he has built, launched and managed pharmaceutical brands, including drug delivery systems, by integrating strategy, pricing, development, clinical planning, manufacturing, branding and promotional requirements into lifecycle plans, demand realization strategies/tactics and affiliate launches. His extensive experience includes the US, EU, Asia and emerging markets.
Mr. Arthur earned a BS in Chemical Engineering from North Carolina State University, a Master of Business Administration from the Duke University Fuqua School of Business, and he is a licensed Professional Engineer and Six Sigma Green Belt. -
Bio
Mark J. Rosenblum
Chief Financial Officer
Mark J. Rosenblum
Chief Financial OfficerMr. Rosenblum is an accomplished financial executive with over 30 years senior management experience within the healthcare and chemical manufacturing industries. Prior to joining Salarius, Mr. Rosenblum served as Chairman, Chief Executive Officer and Director of ActiveCare as well as the Chief Financial Officer of Advaxis. Mr. Rosenblum was employed by Wellman for nearly 20 years, which was later acquired by DAK Americas, serving in various capacities including Chief Accounting Officer. Mr. Rosenblum began his career with Haskins & Sells, CPA (currently known as Deloitte), was a licensed Certified Public Accountant for over 30 years and is currently a member of the American Institute of Certified Public Accountants. Mr. Rosenblum holds both a Masters in Accountancy and a B.S. degree in Accounting from the University of South Carolina.
-
Bio
Nadeem Q. Mirza, MD, MPH
Senior Vice President, Clinical Development
Nadeem Q. Mirza, MD, MPH
Senior Vice President, Clinical DevelopmentDr. Mirza is a seasoned executive physician with 28 years of experience in solid tumors, hematologic malignancies and bone marrow transplantation, including 12 years of clinical research at MD Anderson Cancer Center and 16 years of clinical development and medical affairs in biopharmaceutical industry. Dr Mirza launched several oncology therapies including Campath®, Abraxane®, Nexavar®, Clolar®, Zaltrap®, Venclexta®, and Copiktra®. Dr. Mirza previously served as Chief Medical Advisor with TRIGR Therapeutics, Senior Vice President, Corporate Medical Affairs at Verastem Oncology and Global Head, Hematology and Solid Tumors at Abbvie Oncology. As Vice President, Head of Oncology, North America Medical Affairs at Sanofi Oncology Dr. Mirza was responsible for the medical affairs program that supported 12 products across several oncology indications. Dr. Mirza conducted clinical research at MD Anderson Cancer Center, Houston, Texas from 1992 - 2004.
Dr. Mirza earned a medical degree from the University of Punjab (Lahore, Pakistan) and a Master of Public Health from the University of Texas. -
Bio
Rebecca Griffith-Eskew
Vice President, Clinical Operations
Rebecca Griffith-Eskew
Vice President, Clinical OperationsMrs. Griffith-Eskew has more than 25 years of clinical development and operations experience in oncology drug development, phases I - IV. Mrs. Griffith- Eskew has been a part of multiple successful NDA and BLA submissions, including Ofatumumab, Temozolomide, the early Venetoclax trials in AML, and label expansions for Avelumab. During her career Rebecca has managed, monitored, and overseen on an executive level multiple solid tumor and hematological malignancy trials and oncology portfolios. Mrs. Griffith-Eskew was the head of clinical operations at Immatics, a small biotech company focused in T-Cell therapy, as well as an Executive Director/ Franchise Area Lead overseeing a portfolio of oncology trials at Worldwide Clinical Trials.
Mrs. Griffith-Eskew earned a B.S. in Zoology from the University of Oklahoma and is a candidate for a M.S. in Sport Psychology from Walden University.
Board of Directors
-
Bio
William McVicar, PhD
CHAIRMAN, BOARD OF DIRECTORS
William McVicar, PhD
CHAIRMAN, BOARD OF DIRECTORSDr. McVicar is seasoned pharmaceutical industry executive with more than 30 years of clinical development experience. He most recently served as the Chief Executive Officer of Flex Pharma. Prior to joining Flex Pharma, Dr. McVicar served as Executive Vice President of Pharmaceutical Development, Chief Scientific Officer, and President at Inotek Pharmaceuticals. As Vice President of Development Operations at Sepracor, he oversaw the development, FDA review, and approval of multiple NDAs and SNDAs. Prior to Sepracor, Dr. McVicar held various positions of increasing responsibility at Sandoz, Novartis and Rhone Poulenc Rorer.
Dr. McVicar earned a B.S. in Chemistry from the State University of New York College at Oneonta and his Ph.D. in Chemistry from the University of Vermont. -
Bio
David J. Arthur, MBA
PRESIDENT & CHIEF EXECUTIVE OFFICER
David J. Arthur, MBA
PRESIDENT & CHIEF EXECUTIVE OFFICERMr. Arthur is a senior life sciences executive with more than 25 years of U.S. and global experience leading medical and marketing organizations in product development as well as launching and managing pharmaceutical and device brands. Prior to Salarius Pharmaceuticals, Mr. Arthur was Managing Director of Dacon Pharma. Additionally, He spent more than 20 years with Eli Lilly and Boehringer-Ingelheim in executive roles managing product development, business development, U.S. brands, global commercialization, European regional marketing and financial planning/analysis.
Mr. Arthur earned a B.S. in Chemical Engineering from North Carolina State University, a Master of Business Administration from Duke University, Fuqua School of Business and is a licensed Professional Engineer and Six Sigma Green Belt. -
Bio
Jonathan Lieber
-
Jonathan Lieber
-Mr. Lieber has nearly 30 years of experience in financial and executive management at emerging and growth-stage life sciences companies. As a Chief Financial Officer, Mr. Lieber has helped raise more than $400 million of equity and debt in public and private offerings, including a $110 million initial public offering at Altus Pharmaceuticals, and led myriad strategic and business development transactions, including the successful sale of Xcellerex to GE Healthcare. Mr. Lieber currently serves as Managing Director of Danforth Advisors and as a consulting Chief Financial Officer for several private and public life science companies. Previously, Mr. Lieber worked as an investment banker for almost 10 years, during which time he originated and executed on numerous corporate financings and M&A transactions at SG Cowen and Salomon Brothers. Mr. Lieber earned a B.S. in Business Administration and Finance from Boston University and was awarded a M.B.A. in Finance from New York University Stern School of Business.
-
Bio
Tess Burleson MBA, CPA
-
Tess Burleson MBA, CPA
-Ms. Burleson has more than 20 years of progressive experience in advising and developing key business support operations across a variety of industries, including healthcare, pharmaceutical, and biomedical R&D. Ms. Burleson is the Chief Operating Officer of Translational Genomics Research Institute and the President of TGen Health Ventures. Previously, Ms. Burleson served as Chief Financial Officer at Lovelace Medical Foundation, President at Lovelace Scientific Resources, and as a Senior Associate of Tax, Audit and Advisory Services at KPMG.
Ms. Burleson earned a B.B.A in Accounting and a Master of Business Administration from the University of New Mexico. -
Bio
Paul Lammers, MD, MSc
-
Paul Lammers, MD, MSc
-Dr. Lammers is a senior executive with more than 30 years of experience in the pharmaceutical and biotechnology industry. Dr. Lammers is the President and Chief Executive Officer of Triumvira Immunologics. Prior to joining Triumvira Immunologics, Dr. Lammers served as President & Chief Executive Officer of Mirna Therapeutics, where he raised approximately $160 million in funding before taking the company public on NASDAQ. Previously he was Chief Medical Officer of EMD Serono, a division of Merk KgaA. Additionally, Dr. Lammers held various executive and management roles with BioCyte Therapeutics, Zonagen, Hoechst Marion Roussel and Organon International.
Dr. Lammers earned a M.D and M.S. in Biology and Reproductive Endocrinology from Radboud University in the Netherlands. -
Bio
Bruce McCreedy, PhD
-
Bruce McCreedy, PhD
-Dr. McCreedy has more than 25 years of experience in the development of small molecule and biologic drug products. He has served as the Senior Vice President of cell therapy at Precision Biosciences since September 2015. Prior to his position at Precision Biosciences, Dr. McCreedy was the Executive Vice President of Research and Development and Chief Development Officer of Neximmune and as the managing partner of PharmaNav. Additionally, Dr. McCreedy served as Vice President of Strategic and Clinical Development at Metabolon and as President, Chief Executive Officer and Director at Fulcrum Pharma Developments. Dr. McCreedy also served in various roles at Triangle Pharmaceuticals, Therapyedge, Laboratory Corporation of America Holdings and Roche Biomedical Laboratories.
Dr. McCreedy earned a B.S. in Medical Microbiology from Wake Forest University and a Ph.D. in Microbiology and Immunology from Wake Forest University School of Medicine. -
Bio
Arnold C. Hanish, CPA
-
Arnold C. Hanish, CPA
-Mr. Hanish is a Certified Public Accountant with over 30 years of service within the pharmaceutical industry. Mr. Hanish currently serves on the Board of Directors for Omeros Corporation and has previously served as a member of the Audit Quality Advisory Council for Deloitte and Touche. Previously, Mr. Hanish served in various financial roles at Eli Lilly and Company, including Vice President and Chief Accounting Officer for nearly 20 years. Prior to joining Eli Lilly and company, Mr. Hanish held various managerial positions during his 13-year career at Arthur Young & Company (Ernst Young), including Director of Tax in Indianapolis. He currently serves on the Dean’s Business Advisory Council for the University of Cincinnati College of Business and the Butler University MPA Advisory Board.
Mr. Hanish also served as Chairperson of the Financial Executives International Committee on Corporate Reporting and its SEC and PCAOB subcommittees; he currently is an advisory member to the Committee on Corporate Reporting. Mr. Hanish was a member of the Standing Advisory Group of the PCAOB for several years beginning in 2002.
Mr. Hanish earned a B.A. in Accounting from the University of Cincinnati.